Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mareike Verbeek

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Haematologica|December 28, 2019
Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantationEva Wagner-Drouet, Daniel Teschner, Christine Wolschke, et al.
Bone Marrow Transplantation|September 7, 2023
Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMTJuan Carlos Hernández-Boluda, Diderik-Jan Eikema, Linda Koster, et al.
Bone Marrow Transplantation|December 24, 2025
A European survey on allogeneic haematopoietic cell transplantation for myelofibrosis on behalf of the Chronic Malignancies Working Party of the EBMT: focus on 'real world' experience of JAK inhibitors, splenomegaly management and novel agents in the transplant algorithmAlexandros Rampotas, Jose Maria Aspa-Cilleruelo, Linda Koster, et al.
Bone Marrow Transplantation|March 7, 2026
Length of SARS-CoV-2 shedding in HCT recipients: an Infectious Disease Working Party of EBMT studyMalgorzata Mikulska, Gloria Tridello, Per Ljungman, et al.
American Journal of Hematology|May 26, 2022
Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trialDietrich W Beelen, Matthias Stelljes, Péter Reményi, et al.
American Journal of Hematology|March 21, 2026
Decreased Chronic GvHD With Post-Transplant Cyclophosphamide Versus ATG in Patients With Myelofibrosis Allografted With an Unrelated Donor: A Study From the Chronic Malignancies Working Party of the EBMTYves Chalandon, Edouard F Bonneville, Diderik-Jan Eikema, et al.
Nature Cancer|January 3, 2024
Bacteria and bacteriophage consortia are associated with protective intestinal metabolites in patients receiving stem cell transplantationErik Thiele Orberg, Elisabeth Meedt, Andreas Hiergeist, et al.
The Journal of Clinical Investigation|May 9, 2023
Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donorsAgnes Bonifacius, Britta Lamottke, Sabine Tischer-Zimmermann, et al.
Blood Cancer Journal|October 5, 2021
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemiaChristina Rautenberg, Friedrich Stölzel, Christoph Röllig, et al.
Blood Cancer Journal|April 8, 2025
Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia - long-term follow-up with focus on younger patientsChristina Rautenberg, Jan Moritz Middeke, Christoph Röllig, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Haematologica|December 28, 2019
Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantationEva Wagner-Drouet, Daniel Teschner, Christine Wolschke, et al.
Bone Marrow Transplantation|September 7, 2023
Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMTJuan Carlos Hernández-Boluda, Diderik-Jan Eikema, Linda Koster, et al.
Bone Marrow Transplantation|December 24, 2025
A European survey on allogeneic haematopoietic cell transplantation for myelofibrosis on behalf of the Chronic Malignancies Working Party of the EBMT: focus on 'real world' experience of JAK inhibitors, splenomegaly management and novel agents in the transplant algorithmAlexandros Rampotas, Jose Maria Aspa-Cilleruelo, Linda Koster, et al.
Bone Marrow Transplantation|March 7, 2026
Length of SARS-CoV-2 shedding in HCT recipients: an Infectious Disease Working Party of EBMT studyMalgorzata Mikulska, Gloria Tridello, Per Ljungman, et al.
American Journal of Hematology|May 26, 2022
Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trialDietrich W Beelen, Matthias Stelljes, Péter Reményi, et al.
American Journal of Hematology|March 21, 2026
Decreased Chronic GvHD With Post-Transplant Cyclophosphamide Versus ATG in Patients With Myelofibrosis Allografted With an Unrelated Donor: A Study From the Chronic Malignancies Working Party of the EBMTYves Chalandon, Edouard F Bonneville, Diderik-Jan Eikema, et al.
Nature Cancer|January 3, 2024
Bacteria and bacteriophage consortia are associated with protective intestinal metabolites in patients receiving stem cell transplantationErik Thiele Orberg, Elisabeth Meedt, Andreas Hiergeist, et al.
The Journal of Clinical Investigation|May 9, 2023
Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donorsAgnes Bonifacius, Britta Lamottke, Sabine Tischer-Zimmermann, et al.
Blood Cancer Journal|October 5, 2021
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemiaChristina Rautenberg, Friedrich Stölzel, Christoph Röllig, et al.
Blood Cancer Journal|April 8, 2025
Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia - long-term follow-up with focus on younger patientsChristina Rautenberg, Jan Moritz Middeke, Christoph Röllig, et al.
Pageof 7